GLP-1 and the Pancreas: Risks and Safety

GLP-1 and the pancreas are closely linked: GLP-1 receptor agonists such as semaglutide (Wegovy, Ozempic) and tirzepatide (Mounjaro) act directly on pancreatic beta cells to stimulate insulin release and suppress glucagon. These mechanisms make them effective for managing type 2 diabetes and obesity, but they also mean the pancreas is a key site of both therapeutic action and potential risk. This article explains how GLP-1 medicines affect the pancreas, what the evidence says about pancreatitis risk, who is most vulnerable, and which warning signs should prompt urgent medical attention.

How do GLP-1 medicines affect your pancreas?

GLP-1 receptor agonists bind to receptors on pancreatic beta cells, triggering glucose-dependent insulin release and suppressing glucagon from alpha cells, making the pancreas a primary site of action for this drug class.

GLP-1 receptor agonists act directly on the pancreas by stimulating insulin secretion and suppressing glucagon release in a glucose-dependent manner, meaning these effects occur primarily when blood glucose is elevated.^[1][23] GLP-1 stands for glucagon-like peptide-1, a hormone naturally produced in the gut after eating. Medicines such as semaglutide (Wegovy, Ozempic), liraglutide (Saxenda) and tirzepatide (Mounjaro, which also acts on GIP receptors) mimic or enhance this hormone's activity. These mechanisms are described in the pharmacodynamics sections of the respective UK Summaries of Product Characteristics (SmPCs), available via the Electronic Medicines Compendium (emc).

Within the pancreas, GLP-1 receptors are found on the beta cells of the islets of Langerhans. When activated, they trigger insulin release in proportion to the rise in blood glucose. Because this effect is glucose-dependent, the risk of hypoglycaemia is low when these medicines are used alone. However, the risk of hypoglycaemia increases when they are combined with insulin or sulfonylureas, as noted in the SmPC warnings for each medicine in this class.^[1][2] At the same time, GLP-1 receptor activation suppresses glucagon from alpha cells, further helping to lower blood glucose after meals.

Beyond glucose regulation, some preclinical (animal and laboratory) studies have suggested that GLP-1 receptor activation may support beta cell survival and reduce inflammation within pancreatic tissue. These findings come from animal models and experimental settings; their relevance to human physiology has not been established, and they should not be taken as confirmed benefits in people.

What is well established is that the pancreas is a key site of action for this drug class, which is why understanding the potential risks alongside the benefits is important for anyone considering or already taking these medicines.

Bolt Pharmacy is a GPhC-registered UK online pharmacy offering online weight-management consultations, with prescriber review and pharmacist support, where a range of treatment options may be considered based on individual clinical suitability.

Is there a link between GLP-1 drugs and pancreatitis?

Acute pancreatitis, including necrotising and fatal cases, has been reported with GLP-1 medicines and is listed in UK SmPCs, though large outcome trials have not shown a statistically significant increase versus placebo.

Cases of acute pancreatitis have been reported in people taking GLP-1 receptor agonists. The UK SmPCs for medicines in this class, including semaglutide and tirzepatide (sections 4.4 and 4.8), state that acute pancreatitis has been reported, including post-marketing reports of necrotising pancreatitis and reports with a fatal outcome. The SmPCs do not quantify the magnitude of this risk, and it is therefore not accurate to describe it as small or large based on current labelling.

Importantly, the SmPCs advise that if pancreatitis is suspected, the medicine should be stopped promptly and appropriate clinical assessment sought. If pancreatitis is confirmed, the medicine should not be restarted.

Establishing a causal relationship between GLP-1 medicines and pancreatitis has proved difficult in clinical research. People with type 2 diabetes and obesity, the populations most commonly prescribed these medicines, already carry an elevated baseline risk of pancreatitis due to factors such as gallstones, hypertriglyceridaemia and metabolic dysfunction. Disentangling drug-related risk from background risk requires large, carefully controlled studies, and findings to date have been inconsistent.

Large cardiovascular outcome trials, including LEADER (liraglutide) and SUSTAIN-6 (semaglutide), did not demonstrate a statistically significant increase in pancreatitis events compared with placebo.^[14][15] Nevertheless, regulatory agencies including the MHRA and the European Medicines Agency (EMA) continue to list pancreatitis as an important identified risk requiring monitoring.

Regarding pancreatic cancer, the EMA's Pharmacovigilance Risk Assessment Committee (PRAC) has reviewed the pancreatic safety profile of GLP-1 receptor agonists on multiple occasions. Its conclusions have consistently been that the available evidence does not confirm a causal relationship between these medicines and pancreatic cancer. Subsequent large-scale epidemiological analyses have not confirmed an increased risk, and regulatory bodies have not added pancreatic cancer as a labelled risk for this drug class.^[9][10]

Who is most at risk of pancreatic side effects from GLP-1 treatment?

People with a personal history of pancreatitis, gallstones, hypertriglyceridaemia or heavy alcohol use carry the highest baseline risk and should be assessed carefully before starting a GLP-1 receptor agonist.

Certain individuals face a higher baseline risk of developing pancreatitis and should be assessed carefully before starting a GLP-1 receptor agonist. People with a personal history of pancreatitis are considered at elevated risk, and the UK SmPCs for medicines in this class advise caution in such patients. Family history of pancreatitis is not routinely cited as a risk factor in UK labelling, except where there is a known hereditary pancreatitis syndrome; prescribers will use clinical judgement in those circumstances.

Other risk factors that may increase susceptibility to pancreatic side effects include:

• Gallstones or a history of biliary disease, which are among the most common causes of acute pancreatitis in the general population. The SmPCs for GLP-1 receptor agonists also note gallbladder-related events as a recognised risk, and patients should be counselled to report sudden right-upper-quadrant pain.^[1][2]

• Significantly elevated triglyceride levels (hypertriglyceridaemia), which independently predispose to pancreatitis. Where clinically indicated, checking triglyceride levels before and during treatment is reasonable practice.

• Heavy alcohol use, a well-recognised risk factor for both acute and chronic pancreatitis.

• Obesity, which is associated with more severe pancreatitis episodes when they do occur.

• Rapid weight loss, which can increase bile lithogenicity and gallstone formation, potentially raising biliary pancreatitis risk indirectly.^[21][22]

People with type 2 diabetes who have poorly controlled metabolic parameters may also carry a higher background risk. It is important to recognise that these risk factors relate to pancreatitis in general, not exclusively to GLP-1 treatment, and their presence does not automatically preclude use of these medicines.

A thorough medical history, including any previous episodes of abdominal pain, liver or gallbladder disease, and lipid levels, should inform the prescribing decision. If significant risk factors are present, a prescriber may recommend additional monitoring or consider whether an alternative treatment approach is more appropriate for that individual.

What does the NHS and MHRA say about GLP-1 and pancreatic safety?

The MHRA lists pancreatitis as a labelled risk for GLP-1 medicines, while the EMA's PRAC has consistently found no confirmed causal link between this drug class and pancreatic cancer.

The MHRA has authorised GLP-1 receptor agonists including liraglutide, semaglutide and tirzepatide for use in the UK, and pancreatic safety has been an area of ongoing regulatory scrutiny since this drug class was first introduced. The SmPC for each medicine in this class (section 4.4) includes warnings on pancreatitis and advises that healthcare professionals inform patients of the characteristic symptoms before starting treatment.

NICE guidance on weight management and type 2 diabetes, including technology appraisals covering semaglutide (Wegovy) and tirzepatide (Mounjaro) for weight management, and guideline NG28 covering type 2 diabetes in adults, acknowledges the pancreatitis signal and recommends that prescribers follow the SmPC guidance on monitoring and discontinuation.^[16][17] NICE does not approve medicines but recommends them for NHS use where the evidence supports their clinical and cost effectiveness, and local Integrated Care Boards (ICBs) make commissioning decisions accordingly.

The EMA's Pharmacovigilance Risk Assessment Committee (PRAC) has reviewed the pancreatic safety profile of GLP-1 receptor agonists on multiple occasions. Its conclusions have consistently been that the available evidence does not confirm a causal relationship between these medicines and pancreatic cancer, while maintaining pancreatitis as a labelled risk requiring patient and prescriber awareness.

Healthcare professionals and patients are encouraged to report any suspected adverse reactions, including pancreatic events, through the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk. This reporting system helps the MHRA monitor the real-world safety profile of medicines and identify any emerging signals that may require regulatory action.

Signs of pancreatic problems to watch for during GLP-1 treatment

Persistent, severe upper abdominal pain radiating to the back is the key warning sign of pancreatitis; anyone experiencing this during GLP-1 treatment should seek urgent clinical assessment or attend A&E.

The most important warning sign of pancreatitis during GLP-1 treatment is persistent, severe abdominal pain, typically felt in the upper abdomen and often radiating through to the back. This pain is usually constant rather than colicky, may worsen after eating, and is frequently accompanied by nausea and vomiting. Anyone experiencing these symptoms while taking a GLP-1 receptor agonist should seek urgent clinical assessment. If the pain is severe, does not improve, or is accompanied by fever, rapid heart rate or signs of collapse, they should attend an accident and emergency department or call 999.

If pancreatitis is suspected on clinical grounds, the GLP-1 medicine should be stopped and medical assessment sought without delay. If pancreatitis is confirmed, the medicine should not be restarted, in line with SmPC guidance.

Other symptoms that may suggest a pancreatic problem include:

• Persistent nausea or vomiting that is more severe or prolonged than the mild gastrointestinal side effects commonly seen when starting or increasing the dose of a GLP-1 medicine

• Yellowing of the skin or whites of the eyes (jaundice), which may indicate biliary involvement

• Pale or greasy stools combined with abdominal discomfort; this pattern is more typical of ongoing pancreatic exocrine insufficiency than of acute pancreatitis, but warrants GP review if persistent

• Unexplained weight loss beyond what would be expected from the medicine's intended effect

It is worth noting that mild nausea, bloating and stomach discomfort are common and expected side effects when starting or escalating a GLP-1 receptor agonist, and these do not usually indicate a pancreatic problem. The key distinguishing feature of pancreatitis is the severity and persistence of upper abdominal pain.

Patients should not attempt to self-diagnose pancreatitis. If there is any uncertainty about whether symptoms are a normal side effect or something more serious, contacting NHS 111 for urgent advice is appropriate. A prescriber should always be informed of any new or worsening abdominal symptoms during GLP-1 treatment so that the decision to continue, pause or stop the medicine can be made on clinical grounds.

Scientific References

1. Ozempic 1 mg solution for injection in pre-filled pen (SmPC).
2. Ozempic 0.5 mg solution for injection in pre-filled pen (SmPC).
3. Mounjaro KwikPen 2.5 mg solution for injection in pre-filled pen (SmPC).
4. Tirzepatide | Drugs | BNF.
5. Mounjaro EPAR – product information (tirzepatide).
6. GLP-1 medicines for weight loss and diabetes: what you need to know.
7. Semaglutide | Drugs | BNF.
8. GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists: strengthened warnings on acute pancreatitis, including necrotising and fatal cases.
9. Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC), 23–26 October 2023.
10. Assessment report – Article 53 procedure for GLP-1-based therapies.
11. Investigation into GLP-1-based diabetes therapies concluded.
12. A Systematic Review and Meta-Analysis of Randomised Controlled Trials [pancreatitis risk with GLP-1 RAs].
13. Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (PIONEER 6).
14. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
15. Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis.
16. Tirzepatide for managing overweight and obesity (TA1026).
17. Semaglutide for managing overweight and obesity (TA875).
18. Type 2 diabetes in adults: management (NG28).
19. NG28 – Initial medicines chapter.
20. Adverse reactions to drugs – Yellow Card scheme.
21. Gallbladder motility and gallstone formation in obese patients following very low calorie diets.
22. Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases: A Systematic Review and Meta-analysis of Randomized Clinical Trials.
23. The Roles of Incretin Hormones GIP and GLP-1 in Metabolic and Cardiovascular Health: A Comprehensive Review.
24. Glucagon-like Peptide-1 receptor agonists are not associated with increased risk of pancreatic cancer: A systematic review and meta-analysis.

Frequently Asked Questions